Key result
Discharge beta-blockers linked to lower 1-year mortality in ACS patients with LVEF ≤ 40%.
Why the study?
While beta-blocker therapy benefits ACS patients with LVEF of 40%, its role in patients with LVEF > 40% remains controversial.
Does beta-blocker therapy at discharge reduce 1-year mortality in acute coronary syndrome patients?
Does beta-blocker therapy at discharge reduce 1-year mortality in acute coronary syndrome patients?
Confirms mortality association with discharge beta-blockers in ACS with LVEF ≤40%; leaves open benefit in preserved LVEF.
Aims: While the beneficial effect of beta-blocker (BB) therapy for acute coronary syndrome (ACS) patients with a left ventricular ejection fraction (LVEF) of 40% is established, its role in those with LVEF > 40% is controversial. We assessed the relationship between BB therapy at discharge and 1-year mortality according to LVEF in a large contemporary acute coronary syndrome (ACS) cohort.
No takes yet. Share an insight, caveat, or question.
Maeder et al. (2025) studied this question. Beta-blocker therapy at discharge was evaluated for its impact on 1-year mortality according to left ventricular ejection fraction in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: